1f, with area under the curve, AUC), food intake on refeeding after the i.p
Phase Dual escalation 3 Weeks 21-24 Tirzepatide 12.5 mg/week Cagrilintide 1.7 mg/week Notes Approach maintenance
Compounded medications are not FDA-approved or reviewed before marketing for safety, effectiveness or quality
Semaglutide is an FDA-approved GLP-1 medication that lowers appetite and helps people with obesity or excess weight lose meaningful amounts of weight when paired with a reduced-calorie diet and regular activity
Any extra materials required for research, such as solvents or diluents, must be obtained separately
They are intended to address specific gaps, such as meeting individual patient requirements or providing access during a verified drug shortage